Clinical Trials Directory

Trials / Terminated

TerminatedNCT02088372

Prospective Multi-Center Study on Vanguard With E1 Bearing

Evaluate Clinical Performance of Vanguard Knee With E1 Bearing in Korean Patient Population

Status
Terminated
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Zimmer Biomet · Industry
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population

Detailed description

E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E. Biomet Inc, has received FDA clearance to market tibial polyethylene components made of E1™ for use in the Vanguard total knee replacement system. Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, \& Ascent. The Vanguard Knee includes a streamlined design, rounded sagittal profile, and a deeper trochlear groove. The femoral component is available in Cruciate Retaining (CR), Posterior Stabilizing (PS), and Super Stabilized (SSK). Tibial Bearings are available in various levels of constraint required by the surgeon (CR, PS, AS, etc.). For this study, ONLY Vanguard with PS Bearing will be used. The purpose of the study is to evaluate clinical performance of Vanguard Knee with E1 Bearing in TKA in Korean patient population. The clinical performance will be evaluated based on patient outcomes, radiographic assessment and survivorship.

Conditions

Interventions

TypeNameDescription
DEVICEVanguard with E1 PS BearingEvaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population

Timeline

Start date
2012-11-01
Primary completion
2014-12-01
Completion
2021-02-01
First posted
2014-03-14
Last updated
2022-10-21

Locations

4 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02088372. Inclusion in this directory is not an endorsement.